Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-26T18:17:18.375Z Has data issue: false hasContentIssue false
  • English
  • Français

Dopaminergic Balance and Subtypes of Schizophrenia

Published online by Cambridge University Press:  06 August 2018

R. Dávila ,
M. Zumárraga ,
I. Andia ,
E. Manero ,
F. Retuerto ,
B. Bárcena  and
J. Guimón
R. Dávila
Affiliation:
Department of Neurochemistry, Servicio Vasco de Salud, Zamudio, Vizcaya, Spain
M. Zumárraga
Affiliation:
Department of Neurochemistry, Servicio Vasco de Salud, Zamudio, Vizcaya, Spain
I. Andia
Affiliation:
Department of Neurochemistry, Servicio Vasco de Salud, Zamudio, Vizcaya, Spain
E. Manero
Affiliation:
Department of Neurochemistry, Servicio Vasco de Salud, Zamudio, Vizcaya, Spain
F. Retuerto
Affiliation:
Department of Neurochemistry, Servicio Vasco de Salud, Zamudio, Vizcaya, Spain
B. Bárcena
Affiliation:
Department of Neurochemistry, Servicio Vasco de Salud, Zamudio, Vizcaya, Spain
J. Guimón
Affiliation:
Department of Neurochemistry, Servicio Vasco de Salud, Zamudio, Vizcaya, Spain
Get access Rights & Permissions [Opens in a new window]

Extract

Several attempts have been made to relate subtypes of schizophrenia to dopaminergic status. For example, Crow's hypothesis states that Type I schizophrenia is characterised by positive symptoms, increased activity of the dopaminergic system, good response to neuroleptics, and no brain structural changes; and Type II by negative symptoms, reduced dopaminergic activity, poor response to neuroleptics, and brain structural changes. Testing of this hypothesis has, however, been inconclusive, and it seems more likely that both types are inter-related.

Type
II. Biological Aspects
Information
The British Journal of Psychiatry , Volume 154 , Issue S4: Psychiatric Diagnosis: Nosological, Biological and Psychological Aspects , May 1989 , pp. 57 - 60
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bacopoulos, N. G., Hattox, S. E. & Roth, R. H. (1979) 3,4-Dihydroxyphenylaceti acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. European Journal of Pharmacology, 56, 225–236.Google Scholar
Bowers, M. B. (1984) Family history and CSF homovanillic acid pattern during neuroleptic treatment. American Journal of Psychiatry, 141, 296–298.Google Scholar
Bowers, M. B., Swigar, M. E., Jatlow, P. I., et al (1984) Plasma catecholamine metabolites and early response to Haloperidol. Journal of Clinical Psychiatry, 45, 248–251.Google Scholar
Chang, W. H., Yeh, E. K., Hu, W. H., et al (1986) Acute and chronic effects of Haloperidol on plasma and brain homovanillic acid in the rat. Biological Psychiatry, 21, 374–381.Google Scholar
Clow, A., Theodorov, A., Jenner, P., et al (1980) Changes in rat striatal dopamine turnover and receptor activity during one year of neuroleptic administration. European Journal of Pharmacology, 63, 135–144.Google Scholar
Davidson, M., Giordani, A. B., Mohs, R. E., et al (1987) Short term Haloperidol administration acutely elevates human plasma homovanillic acid concentrations. Archives General Psychiatry, 14, 189–190.Google Scholar
Dávila, R., Zumárraga, M., Manero, E., et al (1984) Adaptacion dopaminergica al tratamiento con neurolepticos. Psiquis, V (1), 29–32.Google Scholar
Dávila, R., Zumárraga, M., Perea, K., et al (1985) Discriminacion bioquimica de pacientes esquizofrenicos. Psiquis, VI, 131–136.Google Scholar
Dávila, R., Zumárraga, M., Andia, I., et al (1986) Rigidity vs. plasticity of dopaminergic system in schizophrenic patients. In Developments in Psychiatry, Vol. 7, pp. 204–206. Amsterdam: Elsevier Science Publications.Google Scholar
Dávila, R., Zumárraga, M., Perea, K., et al (1987) Elevation of plasma homovanillic acid level can be detected within four hours after initiation of Haloperidol treatment. Archives General Psychiatry, 44, 837–838.Google Scholar
Dávila, R., Manero, E., Zumárraga, M., et al (1988) Plasma homovanillic acid as a predictor of response to neuroleptics. Archives General Psychiatry, 55, 564–567.CrossRefGoogle Scholar
Dávila, R., Zumárraga, M., Andia, I., et al. Persistence of cyclicity of the plasma dopamine metabolite homovanillic acid in neuroleptic treated schizophrenic patients. Life Science (in press).Google Scholar
Davis, K. L., Davidson, M. & Mohs, R. C. (1985) Plasma homovanillic acid concentrations and the severity of schizophrenia illness. Science, 227, 1601–1602.Google Scholar
Eaton, W. W. (1986) The epidemiology of schizophrenia. In Handbook of Studies on Schizophrenia (eds Burrows, Normal & Rubinstein), pp. 11–33. Amsterdam: Elsevier Science Publications.Google Scholar
Friedhoff, A. J. (1983) A strategy for developing novel drugs for the treatment of schizophrenia. Schizophrenia Bulletin, 9, 555–562.Google Scholar
Friedhoff, A. J. (1986) A dopamine-dependent restitutive system for the maintenance of mental normality. Annals of New York Academy of Science, 463, 47–52.Google Scholar
Kendler, K. S., Heninger, G. R. & Roth, R. H. (1981) Brain contribution to the Haloperidol-induced increase in plasma homovanillic acid. European Journal of Pharmacology, 71, 321–326.Google Scholar
La Duran, P. M. & Leysen, S. E. (1979) Domperidone, a specific in vitro dopamine antagonist devoid of in vivo central dopaminergic activity. Biochemistry Pharmacology, 28, 2161–2165.Google Scholar
Matthysse, S., Holzman, P. S. & Lange, K. (1986) The genetic transmission of schizophrenia: Application of mendelian latent structure analysis to eye tracking dysfunction in schizophrenia and affective disorder. Journal of Psychiatric Research, 20, 57–67.CrossRefGoogle ScholarPubMed
Meltzer, H. Y. (1987) Biological studies in schizophrenia. Schizophrenia Bulletin, 13, 77–111.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) The brief psychiatric rating scale. Psychology Reports, 10, 799–812.Google Scholar
Pickar, D., Labarca, R., Linnoila, M., et al (1984) Neurolepticinduced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science, 225, 954–957.Google Scholar
Pickar, D., Labarca, R., Doran, A. R., et al (1986) Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Archives General Psychiatry, 43, 669–676.Google Scholar
Tobin, A. J. (1987) Molecular biology and schizophrenia. Schizophrenia Bulletin, 13, 199–203.Google Scholar
Van Kammen, D. P., Van Kammen, W. D., Mann, L. S., et al (1986) Dopamine metabolism in the cerebrospinal fluid of drug free schizophrenic patients with and without cortucak atrophy. Archives General Psychiatry, 43, 978–983.Google Scholar
Zumárraga, M., Andia, I., Barcena, B., et al (1987) A liquid chromatographic method for determination of homovanillic acid in plasma with electochemic detection. Clinical Chemistry, 33, 72–76.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.